Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

716
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
716
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of morbid obesity with atopic dermatitis differs by race and sex in a dermatology clinic cohort.

Journal of the American Academy of Dermatology·2026
Same author

Sphenopalatine Ganglion Radiofrequency Ablation for Severe Facial Rosacea Manifestations.

Pain practice : the official journal of World Institute of Pain·2026
Same author

Correction: Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.

Dermatology and therapy·2026
Same author

Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).

Dermatology and therapy·2026
Same author

Dupilumab subgroup responder analysis: a <i>post hoc</i> analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis.

The Journal of dermatological treatment·2026
Same author

Cross-Talk between Neurons and Immune Cells in Pruritus: from Mechanisms To Medicines.

Current allergy and asthma reports·2026

Related Experiment Video

Updated: Mar 15, 2026

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
04:59

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors

Published on: September 27, 2019

13.2K

Paraneoplastic Itch Management.

Brandon Rowe, Gil Yosipovitch

    Current Problems in Dermatology
    |September 1, 2016
    PubMed
    Summary

    Paraneoplastic itch, a symptom linked to cancer, often accompanies lymphoproliferative disorders or cholestatic solid tumors. Effective treatment focuses on the underlying malignancy, with other therapies available for refractory cases.

    Area of Science:

    • Oncology
    • Dermatology
    • Internal Medicine

    Background:

    • Paraneoplastic itch is a systemic reaction to an underlying malignancy.
    • It is frequently associated with lymphoproliferative malignancies and solid tumors causing cholestasis.
    • This type of itch can manifest with or without a primary rash, or alongside conditions like erythroderma, acanthosis nigricans, dermatomyositis, Grover's disease, and eruptive seborrheic keratosis.

    Purpose of the Study:

    • To review the etiology, clinical presentation, and management of paraneoplastic itch.
    • To highlight the association between paraneoplastic itch and various malignancies.
    • To discuss therapeutic strategies for paraneoplastic itch, including malignancy-targeted treatments and alternative options.

    Main Methods:

    • Literature review of paraneoplastic itch.

    Related Experiment Videos

    Last Updated: Mar 15, 2026

    Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
    04:59

    Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors

    Published on: September 27, 2019

    13.2K
  • Analysis of associated malignancies and dermatologic conditions.
  • Summary of treatment modalities.

    • Main Results:

    • Paraneoplastic itch is strongly linked to lymphoproliferative malignancies and cholestatic solid tumors.
    • Dermatologic manifestations can vary, including erythroderma and eruptive seborrheic keratosis.
    • Treatment primarily involves addressing the underlying cancer.

    Conclusions:

    • Management of paraneoplastic itch requires a dual approach: treating the primary malignancy and managing symptoms.
    • For treatment-refractory cases, pharmacologic interventions such as SSRIs, mirtazapine, gabapentin, thalidomide, opioids, aprepitant, and HDAC inhibitors show efficacy.